By Nick Johnson (Apyx) In 2024 Shareholder News, J-Plasma, RenuvionPosted October 24, 2024APYX MEDICAL CORPORATION TO RELEASE THIRD QUARTER OF FISCAL YEAR 2024 FINANCIAL RESULTS ON NOVEMBER 8, 2024 READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, RenuvionPosted August 13, 2024RENUVION NAMED #1 TRUSTED BODY CONTOURING TECHNOLOGY BY DOCTORS* READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, J-Plasma, RenuvionPosted August 8, 2024APYX MEDICAL CORPORATION ANNOUNCES PEER-REVIEWED CLINICAL PUBLICATION COMPARING THE USE OF RENUVION TO A COMPETING TECHNOLOGY FOLLOWING LIPOSUCTION OR BODY CONTOURING PROCEDURES READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, J-Plasma, RenuvionPosted August 8, 2024APYX MEDICAL CORPORATION REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS; UPDATES FULL YEAR 2024 FINANCIAL OUTLOOK READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, J-Plasma, RenuvionPosted July 25, 2024APYX MEDICAL CORPORATION TO RELEASE SECOND QUARTER OF FISCAL YEAR 2024 FINANCIAL RESULTS ON AUGUST 8, 2024 READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, RenuvionPosted June 26, 2024APYX MEDICAL CORPORATION LAUNCHES THE “RENEWING LIVES” GIVE-BACK CAMPAIGN PROVIDING TREATMENTS WITH RENUVION TO BENEFIT PHYSICAL APPEARANCE AND MENTAL HEALTH READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, J-Plasma, RenuvionPosted May 9, 2024APYX MEDICAL CORPORATION REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS; REAFFIRMS FULL YEAR 2024 FINANCIAL OUTLOOK READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, J-Plasma, RenuvionPosted May 9, 2024APYX MEDICAL CORPORATION ANNOUNCES BOARD LEADERSHIP TRANSITION READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, J-Plasma, RenuvionPosted April 25, 2024APYX MEDICAL CORPORATION TO RELEASE FIRST QUARTER OF FISCAL YEAR 2024 FINANCIAL RESULTS ON MAY 9, 2024 READ MORE
By Nick Johnson (Apyx) In 2024 Shareholder News, RenuvionPosted April 11, 2024APYX MEDICAL CORPORATION SHOWCASES NEW DATA AND TREATMENT INSIGHTS AT THE RENUVION USERS’ SUMMIT READ MORE
